Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.1952W HIGH $17.19
Volume
23.67 K
Value Traded
59.81 K
Short % Float
0.39%
Days to Cover
1.6
+0.9%Week
-9.7%1 Month
+1.52%3 Month
-33.4%6 Month
-97.92%5 Year
-97.92%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
18.11 M
EPS (TTM)
-2.49
P/E Ratio
-
Ent. Value
-1.90 M
Total Shares
5.41 M
Float Shares
5.14 M
Insiders
5.02%
Institutions
41.51%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NEUP Catalyst Timeline
Dated clinical, regulatory and corporate events for Neuphoria Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Neuphoria Therapeutics Inc.
162Total events
6Upcoming
34Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Debt Royalty FinancingCorporate
Non-binding term sheet for up to $25 million Debt Financing with BlackRock
◆Management ChangeCorporate
Lynx1 Master Fund LP intends to nominate individuals for election to Board of Directors at 2025 Annual Meeting
◆Pipeline PrioritizationCorporate
Strategic review of alternatives initiated; R&D expenditures paused for BNC210 in PTSD
◆Management ChangeCorporate
Proxy contest: Neuphoria recommends voting for its nominees Peter Miles Davies and David Wilson
◆Pipeline PrioritizationCorporate
Initiation of strategic review to maximize stockholder value
◆Quarterly UpdateCorporate
Engaged H.C. Wainwright & Co. as financial advisor for strategic review
◆AcquisitionCorporate
Received unsolicited non-binding indication of interest from Lynx1 Master Fund LP to acquire all outstanding shares at $5.20 per share
▼Topline ReadoutBNC210Clinical Data
AFFIRM-1 Phase 3 trial of BNC210 missed primary and secondary endpoints
social anxiety disordersource ↗
▼Program DiscontinuationBNC210Corporate
Halted development of BNC210 in social anxiety disorder
social anxiety disordersource ↗
▼Primary Endpoint MissedBNC210Clinical Data
AFFIRM-1 Phase 3 trial missed primary and secondary endpoints
social anxiety disordersource ↗
▼Program DiscontinuationBNC210Corporate
Halted development of BNC-210 in SAD
social anxiety disordersource ↗
▼Trial DiscontinuedBNC210Trial
AFFIRM-1 Phase 3 trial missed primary and secondary endpoints; development halted in SAD
social anxiety disordersource ↗
▼Primary Endpoint MissedBNC210Clinical Data
AFFIRM-1 Phase 3 trial of BNC210 for acute treatment of SAD did not meet primary endpoint
social anxiety disordersource ↗
◆Pipeline PrioritizationBNC210Corporate
Evaluation of next steps for BNC210 in PTSD
post-traumatic stress disordersource ↗
◆Pipeline PrioritizationCorporate
Strategic review initiated; cost-cutting program and financial advisor appointed
◆Topline ReadoutBNC210Clinical Data
Topline Phase 3 data for BNC-210 in SAD expected early Q4 2025
social anxiety disordersource ↗
▲Last Patient Last VisitBNC210Trial
Last patient last visit in AFFIRM-1 Phase 3 trial of BNC-210 in SAD
social anxiety disorder (SAD)source ↗
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲Enrollment CompleteBNC210Trial
Target enrollment of 332 participants completed in AFFIRM-1 Phase 3 trial of BNC-210 for SAD
social anxiety disordersource ↗
◆Topline ReadoutBNC210Clinical Data
Topline data expected from AFFIRM-1 Phase 3 study in Q3 2025
Social Anxiety Disordersource ↗
◆Development Candidate NominationPreclinical
Nomination of development candidate for 2nd generation 7 nAChR NAM
◆Oral PresentationBNC210Presentation
Presentation at ASCP 2025 Annual Meeting
social anxiety disordersource ↗
◆Enrollment UpdateBNC210Trial
BNC210 continues to enroll into AFFIRM-1 Phase 3 study in Social Anxiety Disorder
Social Anxiety Disordersource ↗
◆Trial InitiationMK-1167Trial
Merck-led Phase 2 trial of MK-1167 in Alzheimer's disease continues
Alzheimer's diseasesource ↗
●IpoCorporate
Neuphoria Therapeutics rings Nasdaq Opening Bell to celebrate redomiciliation and launch
▲Milestone PaymentCorporate
Neuphoria to receive $15M milestone payment from Merck triggered by Phase 2 trial initiation of MK-1167
▲Trial InitiationMK-1167Trial
Merck initiates Phase 2 trial of MK-1167 for Alzheimer's disease dementia
Alzheimer's disease dementiasource ↗
●IpoCorporate
Supreme Court of New South Wales approves re-domiciliation; Neuphoria shares expected to begin trading on Nasdaq under NEUP
▲AcquisitionCorporate
Neuphoria completes re-domiciliation from Australia to US, becoming ultimate parent of Bionomics
◆AcquisitionCorporate
Amending agreement to Scheme Implementation Agreement between Bionomics and Neuphoria
◆Management ChangeCorporate
Intention to re-domicile from Australia to the United States via scheme of arrangement
▲Trial InitiationTrial
Merck partnered α7 PAM program advanced to Phase 2
Alzheimer's disease dementiasource ↗
▲Enrollment UpdateBNC210Trial
Robust enrollment in BNC210 Phase 3 SAD trial
Social Anxiety Disordersource ↗
◆First Patient DosedBNC210Trial
First patient dosed in Phase 3 program for BNC210 in SAD expected Q1 2024
Social Anxiety Disordersource ↗
Past FDA Catalysts and PDUFA Decisions
How NEUP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-09-30 | BNC210 (oral solid tablet) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 45%
Micro Cap(rank 296 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BNC210 Small moleculeCompletedNCT05193409 | Social Anxiety Disorder | Phase 3 | COMPLETED | 521 | Oct 17, 2022 | ||||||
| BNC210 Small moleculeCompletedNCT03548194 | Agitation in the Elderly | Phase 2 | COMPLETED | 38 | Apr 24, 2019 | ||||||
| BNC210 Small moleculeCompletedNCT04951076 | Post-Traumatic Stress Disorder | Phase 2 | COMPLETED | 405 | Aug 14, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every NEUP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BNC210 | Post-Traumatic Stress Disorder (PTSD) | Phase 2b | 2023-09-28 | total patients: 212; primary endpoint p value: 0.048; secondary endpoint depressive symptoms p value: 0.04; secondary endpoint sleep p value: 0.041; adverse events: headache >5%, nausea >5%, fatigue >5%, hepatic enzyme increase 14 (13.3%) patients treated with BNC210 vs 2 (0.19%) in the placebo groupRead More | Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) ATTUNE trial met its primary endpoint showing BNC210 treatment led to Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP10% Owner | Buy | 639,110 875,328 held | $5.14 | 10/21/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in NEUP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 207.33 K | 47.44 K |
NEUP Institutional Ownership Trends
NEUP Short Interest
Shares sold short, counted twice a month.
0.39%
Short % of Float
of tradable shares sold short
20.0K
Shares Sold Short
-19.0% vs prior count
1.6 Low
Days to Cover
trading days of normal volume to buy every short share back
12.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NEUP ranks across every disease it competes in
Competitive Position is a premium feature
See how NEUP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNEUP News
NEUP▲ +17.7%on this news
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Scancell and Neuphoria Therapeutics have announced an all-share merger, creating a combined entity that will operate under the Scancell name and seek a Nasdaq listing. The merger, which has been unanimously approved by both companies' boards, aims to advance Scancell's immunotherapy pipeline, particularly the lead program iSCIB1+. The transaction includes significant financing to support a Phase 3 trial for iSCIB1+ in advanced melanoma.
Read more →NEUPNeuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Neuphoria Therapeutics has confirmed ongoing discussions with Scancell Holdings plc regarding a potential collaboration. This engagement suggests a strategic move to enhance their development initiatives. The talks indicate a positive outlook for Neuphoria as it seeks to expand its operational capabilities.
Read more →NEUP▲ +6.3%on this news
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
Neuphoria Therapeutics Inc. has received a recommendation from Institutional Shareholders Services (ISS) for shareholders to vote for its director nominees on the WHITE proxy card. This recommendation comes amid a proxy contest initiated by Lynx1 Capital Management. Neuphoria's board is recognized for its proactive measures following the Phase 3 trial results of BNC210, which missed its endpoints, prompting a strategic review.
Read more →NEUPNeuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
Neuphoria Therapeutics has responded to Lynx1's revised interest in acquiring the company at a lower bid of $4.75 per share, which the board deems inadequate. The company is currently conducting a strategic review of alternatives for maximizing stockholder value and has received significant interest from various parties. Neuphoria's board emphasizes the importance of evaluating all proposals while ensuring that their own strategic processes are not overlooked. They encourage stockholders to support their existing board nominees amid the ongoing proxy contest with Lynx1.
Read more →NEUPNeuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
Neuphoria Therapeutics has released a statement addressing allegations made by Lynx1 Master Fund, which it claims are misleading and intended to distract shareholders. The company urges investors to support its board nominees while disputing Lynx1's criticisms regarding its strategic plans and board actions. Neuphoria asserts it has maintained transparency and has a robust strategic review process. The situation highlights an ongoing proxy contest where shareholder confidence is a significant concern.
Read more →NEUPNeuphoria Therapeutics Inc. Sends Letter to Stockholders
Neuphoria Therapeutics Inc. has issued a letter to its stockholders urging them to vote in favor of its two nominated board members at the upcoming 2025 Annual Meeting. The company is undergoing a strategic review aimed at maximizing value for all stockholders, particularly in light of its upcoming clinical trial data. Additionally, Neuphoria is raising capital to ensure financial stability, mitigating risks associated with clinical outcomes and potential takeover threats. The company expresses confidence in its nominated directors' ability to navigate this important phase effectively.
Read more →NEUPNeuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value
Neuphoria Therapeutics has initiated a strategic review to explore options for maximizing stockholder value, including potential mergers and acquisitions. The company has engaged H.C. Wainwright & Co. as its financial advisor. Additionally, Neuphoria received an unsolicited acquisition offer from Lynx1 Master Fund LP at $5.20 per share. The review comes after the company halted development of its lead drug candidate, BNC210, due to unmet clinical trial endpoints.
Read more →NEUPNeuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
Neuphoria Therapeutics has adopted a limited-duration stockholder rights plan to safeguard the integrity of its strategic review process amid significant stock accumulation by certain investors. The plan aims to ensure fair participation for all stockholders and allows the Board time to make informed decisions. However, the company recently halted development of its lead drug candidate following a failed clinical trial.
Read more →NEUP▼ -68.5%on this news
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
Neuphoria Therapeutics announced that its AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder failed to meet its primary and secondary endpoints. As a result, the company will halt the development of its SAD program and conduct a strategic review of its operations. Neuphoria will also explore further development of BNC210 for PTSD.
Read more →NEUPNeuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
Neuphoria Therapeutics has achieved the last patient last visit milestone in its AFFIRM-1 Phase 3 trial for BNC-210, aimed at treating social anxiety disorder. The company reported a net loss of $0.4 million for the fiscal year ending June 30, 2025, a significant reduction from the previous year's loss. Neuphoria's cash position is expected to support operations through Q2 2027, with topline data from the trial anticipated in early Q4 2025.
Read more →NEUP▼ -8.3%on this news
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
Neuphoria Therapeutics has completed the target enrollment of 332 participants in its Phase 3 AFFIRM-1 trial for BNC-210, a treatment for social anxiety disorder (SAD). The trial is designed to evaluate the safety and efficacy of a single acute dose of BNC-210 compared to a placebo. The company anticipates that Phase 3 data will be available early in the fourth quarter of 2025. BNC-210 has received FDA Fast Track designation, which supports its development for SAD and other anxiety-related disorders.
Read more →NEUP▼ -7.2%on this newsshared move
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Neuphoria Therapeutics Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Spyros Papapetropoulos will discuss the company's advancements in treatments for neuropsychiatric disorders, including their lead drug candidate BNC-210 for social anxiety disorder and PTSD. The presentation will be available on demand starting September 5.
Read more →NEUPNeuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
Neuphoria Therapeutics Inc. announced its upcoming presentation at the ASCP 2025 Annual Meeting. The company is focused on developing treatments for neuropsychiatric disorders, particularly its lead candidate BNC210 for social anxiety disorder and PTSD. Neuphoria also has a partnership with Merck for early-stage clinical trials targeting cognitive deficits in Alzheimer's disease.
Read more →NEUPNeuphoria Provides First Quarter 2025 Business Updates
Neuphoria Therapeutics has reported steady progress in its clinical pipeline for Q1 2025. The company is advancing its lead candidate, BNC210, in a Phase 3 study for Social Anxiety Disorder, with topline data anticipated in Q3. Additionally, its partnered asset MK-1167 is making strides in a Phase 2 trial for Alzheimer's disease.
Read more →NEUPNeuphoria Provides a Review of 2024 and Highlights 2025 Plans
Neuphoria Therapeutics Inc. reviewed its progress in 2024 and outlined its plans for 2025. The company reported that its BNC210 program for social anxiety disorder has entered Phase 3, while its collaboration with Merck for Alzheimer's treatment has moved to Phase 2. Neuphoria aims to enhance shareholder value by efficiently advancing its pipeline.
Read more →NEUP▼ -5.2%on this news
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
Neuphoria Therapeutics Inc. will ring the Nasdaq Opening Bell on March 3, 2025, to celebrate its redomiciliation to the US and the launch of the company. CEO Spyros Papapetropoulos emphasized the dedication of the team in positioning Neuphoria for long-term success. The event will be broadcast live from Times Square, New York City.
Read more →NEUPNeuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
Neuphoria Therapeutics Inc. announced it will receive a $15 million milestone payment from Merck due to the initiation of a Phase 2 clinical trial for MK-1167, aimed at treating Alzheimer's disease symptoms. This payment marks the second milestone achieved in Neuphoria's collaboration with Merck, who has the potential to provide up to $450 million in future milestone payments. Neuphoria's drug pipeline includes various candidates targeting neuropsychiatric disorders, further emphasizing its commitment to developing impactful treatments.
Read more →NEUPDESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Neuphoria Therapeutics Inc., a Delaware corporation (the "Company") is a summary only. This summary is subject to the General Corporation Law
Neuphoria Therapeutics Inc. has outlined details regarding its capital stock under Delaware law. The company is authorized to issue a significant number of common and preferred shares and has specific provisions regarding voting rights, dividends, and liquidation rights. Additionally, the certificate of incorporation includes various measures that may hinder stockholder influence over board composition and corporate control, potentially complicating takeover attempts.
Read more →NEUPNeuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
Neuphoria Therapeutics Inc. has completed its re-domiciliation from Australia to the United States, establishing itself as the ultimate parent company of Bionomics Limited. Trading of its common stock under the ticker symbol 'NEUP' on the Nasdaq is set to commence on December 24, 2024. Additionally, Neuphoria will issue stock options and warrants to existing holders of Bionomics securities. This strategic move is aimed at enhancing its operations in the US market and advancing its therapeutic candidates.
Read more →NEUPSupreme Court of New South Wales approves Bionomics' re-domiciliation Adelaide, Australia and Cambridge, Mass.
Bionomics Limited has received approval from the Supreme Court of New South Wales for its re-domiciliation from Australia to the United States. This change will result in Neuphoria Therapeutics Inc. becoming the ultimate parent company of Bionomics. The implementation date for this Scheme is set for December 23, 2024, with Neuphoria shares poised to trade on Nasdaq under the symbol 'NEUP' starting December 24, 2024. This transition marks a significant shift for the company as it seeks to enhance its operations in the U.S. market.
Read more →About Neuphoria Therapeutics Inc.
Headquarters100 SUMMIT DR, BURLINGTON, MA, 01803
BIOPHARMAWATCH ELITE PLUS
Trade the next NEUP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime